CLINICAL_TRIALS
trial_result
· 2022-05-17
Clinical Trial Update: Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma [Phase 2]
Summary
Phase 2 clinical trial investigating avelumab with IL-15 in clear-cell renal carcinoma has been terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Clear-Cell Renal Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-05-17